Jane Street’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Jane Street’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$481K	Buy	+99,200	New	+$396K	﹤0.01%	8114
2024 Q1	–	Sell	-10,200	Closed	-$155K	–	10218
2023 Q4	$155K	Sell	10,200 -13,500	-57%	-$197K	﹤0.01%	8380
2023 Q3	$475K	Sell	23,700 -1,700	-7%	-$43.1K	﹤0.01%	6372
2023 Q2	$717K	Buy	25,400 +9,000	+55%	+$216K	﹤0.01%	5758
2023 Q1	$282K	Buy	+16,400	New	+$332K	﹤0.01%	7298
2022 Q4	–	Sell	-19,700	Closed	-$427K	–	10300
2022 Q3	$427K	Buy	19,700 +9,600	+95%	+$263K	﹤0.01%	6975
2022 Q2	$284K	Sell	10,100 -5,900	-37%	-$156K	﹤0.01%	7696
2022 Q1	$738K	Buy	16,000 +9,400	+142%	+$507K	﹤0.01%	6748
2021 Q4	$555K	Buy	+6,600	New	+$511K	﹤0.01%	7063
2021 Q3	–	Sell	-33,000	Closed	-$1.76M	–	10878
2021 Q2	$1.76M	Buy	+33,000	New	+$1.77M	﹤0.01%	4581

Other funds holding ZNTL

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Jane Street's ZNTL Position: Q2 2026 in Review

Jane Street reduced its Zentalis Pharmaceuticals (ZNTL) stake by 97% in Q2 2026, selling an estimated $1.9M and leaving 14,395 shares worth $69.8K. The position accounts for ﹤0.01% of the portfolio, ranked #10787.

Jane Street first reported a position in ZNTL in Q2 2020 and has held it in 20 quarters since. The position peaked at $1.96M in Q1 2024. 113 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

Jane Street held 14,395 shares of Zentalis Pharmaceuticals worth $69.8K as of Q2 2026.
Jane Street sold 475,944 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $1.9M.
Zentalis Pharmaceuticals made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #10787 holding.
Jane Street first reported a position in Zentalis Pharmaceuticals in Q2 2020 and has held it in 20 quarters since.
Jane Street's Zentalis Pharmaceuticals position peaked at $1.96M in Q1 2024.
113 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.